Autologous transplantation continues to be the cornerstone of younger and fit multiple myeloma patients. It is known that frontline induction therapy before transplantation can influence post-transplant results. Therefore, best frontline treatment for transplant-eligible patients should be based on best available evidence to guide therapy. Furthermore, until now due to data scarcity, it was not possible to thoroughly compare lenalidomide to other regimens in this setting. We performed a systematic and cardiac with PAD regimens. Our study endorses current recommendations on combined immunomodulatory drugs and proteasome inhibitors frontline regimens (in triplets) in transplant-eligible multiple myeloma patients, but also formally demonstrates the favorable performance of lenalidomide in overall and progression-free survival, when compared with bortezomib/thalidomide protocols.
| INTRODUCTION
Multiple myeloma (MM) is the second most common hematologic malignancy worldwide, 1,2 and its incidence has increased steadily (specially among non-Hispanic whites and non-Hispanic black men). 3 Over the last two decades, the introduction of different classes of agents has improved overall survival (OS) for both autologous transplant-eligible and ineligible patients. 3, 4 This therapeutic arsenal includes proteasome inhibitors, immunomodulatory imide drugs, histone deacetylase inhibitors, monoclonal antibodies, along with corticosteroids and alkylating drugs. 5 Frontline treatment for transplant-eligible MM patients is an essential treatment step and should be carefully planned in order to obtain a maximal response without excessive toxicity, while allowing for hematopoietic graft harvesting. Quality of induction therapy response has been shown to improve post-transplant survival. 6 However, as new agents are continuously being developed, selecting a specific combination of drugs became an ever-increasing challenge.
To fulfill this methodological gap, an innovative approach of network meta-analysis, the mixed treatment comparison (MTC), has been developed allowing for simultaneous multiple comparisons among treatments through direct and indirect evidence, also ranking therapeutic approaches according to their probability of being the best among those tested. With this tool, all selected treatments, which were and probably would not be compared on a clinical trial setting, can have their relative effects weighted against each other simultaneously. [7] [8] [9] A recently published network meta-analysis has covered a similar subject, 10 but unfortunately it failed to gather information on lenalidomide, which is now available through the results of the Myeloma XI trial. 11, 12 Lenalidomide has been associated with hematopoietic progenitor cell graft harvesting failure, 13 a fact that has hindered its use in transplant-eligible patients in the past. Newer harvesting approaches however had made it possible for these patients to undergo autologous transplantation, 14 mitigating these obstacles.
In order to define, among current and past available therapeutic options, the best frontline treatment approaches for patients eligible to autologous transplantation, we have conducted a systematic review and MTC meta-analysis comprising all available randomized clinical trials to date.
| METHODS

| Information sources and search strategy
We have performed a comprehensive systematic review in order to identify all clinical trials comparing treatment approaches enrolling MM patients. Search strategy comprised terms defining MM and related disorders, available active drugs, and a sensitive filter strategy for randomized clinical trials. [15] [16] [17] Included databases were MEDLINE, Embase, LILACS, SciELO, Cochrane CENTRAL, and proceedings from major international meetings in hematology and oncology. We have also hand-searched references from all retrieved randomized clinical trials and prior systematic reviews. Search strategy for databases screened are available in Table 1 .
Duplicates were excluded before proceeding to study selection.
All titles and abstracts retrieved were screened independently by teams of two researchers. Full-text articles also had its eligibility evaluated by two independent researchers. The last date of the search was May 1st 2018. The review protocol has been registered in the PROSPERO International Prospective Register of Systematic Reviews (registration number: CRD42018085107) and also approved by institutional ethics committee. We have followed Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for conducting this study and reporting our results.
18,19
| Eligibility criteria
Selected patient population involved newly diagnosed transplant-eligible MM patients. Only randomized phase 2/3 clinical trials comparing two or more therapeutic approaches for MM, with or without blinding, were included in the study. Abstracts or unpublished data were allowed to be included if they reported sufficient data to extraction.
No language or age restriction was applied.
Studies were excluded if there were no randomization procedure reported or if design was considered unclear. No prior treatment was allowed except for brief corticosteroid exposure. Refractory/relapsed MM patients' studies were also excluded. Ancillary treatment approaches as bisphosphonates, kyphoplasty/vertebroplasty, radiation therapy, colony stimulating factors, or erythropoietin were allowed if they were evenly distributed on trial arms, but trials comparing only bisphosphonate use were not considered for the purpose of this meta-analysis. Interferon treatment was also not included in the systematic review due to its obsolescence within current therapy. Studies were also excluded if they did not report data on OS and/or progression-free survival (PFS) hazard ratios (HR).
| Study selection and data extraction
Eight reviewers (L.S., D.M., F.S.F., M.R.R., M.S., C.F.P., V.D.M., A.P.S.) participated in the screening and full-text evaluation. All abstracts screened and articles selected were reviewed and extraction proceeded by two of the eight reviewers, while a third reviewer would intervene (R.A.R.) if there was any discordance over data extracted.
Data extracted were as follows: title and reference details (first author, year of publication, study acronym, period of patient enrollment, site of the study), study population characteristics (age, sex, median fol- Embase Population ("multiple myeloma"/exp OR "multiple myeloma" OR "myeloma" OR "multiple myelomas" OR "plasma-cell myeloma" OR "plasma-cell myelomas" OR "myelomatosis" OR "myelomatoses" OR "plasma cell myeloma" OR "plasma cell myelomas" OR "kahler disease" OR "POEMS")
Intervention ("dexamethasone"/exp OR "dexamethasone") OR ("prednisone"/exp OR "prednisone") OR ("prednisolone"/exp OR "prednisolone") OR ("methylprednisolone"/exp OR "methylprednisolone") OR ("betamethasone"/exp OR "betamethasone") OR ("cyclophosphamide"/ exp OR "cyclophosphamide") OR ("melphalan"/exp OR "melphalan"/exp) OR ("bendamustine"/exp OR "bendamustine") OR ("bortezomib"/exp OR "bortezomib") OR ("carfilzomib"/exp OR "carfilzomib") OR ("salinosporamide A"/exp OR "salinosporamide A" OR "Marizomib" OR "NPI 0052" OR "NPI-0052") OR ("ixazomib"/exp OR "ixazomib" OR "MLN9708" OR "MLN2238") OR ("oprozomib"/exp OR "oprozomib" OR "ONX0912") OR ("delanzomib"/exp OR "delanzomib" OR "CEP-18770" OR "CEP18770" OR "CEP 18770") OR ("thalidomide"/exp OR "thalidomide") OR ("lenalidomide"/exp OR "lenalidomide") OR ("pomalidomide"/exp OR "pomalidomide")
Outcome Omitted (for increased sensitivity). of patients experiencing any grade 3 to 4 events (one or more episodes) during study period. If there were any data not clearly reported on manuscripts from reviewed articles or supplemental material, correspondent authors were contacted and asked to provide needed information. All data were extracted independently and registered on separate electronic spreadsheets, which were compiled and compared afterwards.
ECR Filter
| Quality assessment
Selected studies were assessed for quality and risk of bias considering recommendations from The Cochrane Collaboration 20 group (including items such as random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete data outcome, selective reporting). We have also evaluated early trial interruption due to efficacy as a possible bias. 21 This evaluation was also peer-reviewed, and disparities were resolved by a third author. Where information for bias assessment was not reported, correspondent author was contacted and asked to provide study details. If no contact could be established, evaluated item was ranked unclear. Outcome Omitted (for increased sensitivity).
| Mixed treatment comparison network metaanalysis
ECR Filter
Omitted (for increased sensitivity).
FIGURE 1 PRISMA flowchart for study selection and review [CrI]), whether a risk ratio (RR) or a HR (or other endpoint measure).
Contribution from this technique is that precision of estimates can be improved pending on completeness of meta-analysis network, also allowing inclusion of more than two-arm trials. Also, this method of meta-analysis is able to rank all treatments in order to quantify probability of being best ranked overall (for each specific outcome).
Goodness of fit of the models was evaluated by means of residual deviance and deviance information criteria. Deviance information criteria value was used as a parameter to compare model adjustment between random and fixed models. Eventually, MTC analyses were performed considering a fixed effect model, due to the fact that all comparisons derived from one trial each. Similarity assumption (based on the premise that the true treatment effect comparing any two interventions would be similar across all trials 3 | RESULTS
| Study selection
PRISMA flowchart for study selection and search strategy is depicted in Figure 1 . In the time frame covered by this systematic review, a total of 17360 studies, including full articles or meeting abstracts, were peer-reviewed (after excluding duplicate entries). From these references, 21 published articles deriving from 10 different RCT, with a total of 6474 patients, were eventually considered eligible for inclusion in meta-analysis. Table 2 , and specifications of each therapeutic protocol are available in Table 3 . The RCT including lenalidomide 11, 12 reported only survival outcomes. All studies performed transplantation 
| Quality assessment
Quality assessment summary is presented in Table 4 . Overall, risk assessment was compromised by underreporting of randomization and concealment methods in most of the trials and non-blinding of participants and personnel.
| Treatment group allocation, network assembling, and consistency checking
We have arbitrarily allocated similar multidrug protocols based on their drug profile, resulting in 11 individual treatment groups: TT2- 11, 12 and Dex 44 (High Dose Dexamethasone). Network plots for all outcomes are presented in Figure 2 . 
| Survival analysis
| Safety/Toxicity
We have evaluated the risk of six different grade 3 to 4 AE groups:
thromboembolic, neurological, infectious, hematological, gastrointestinal, and cardiac events. Simultaneous comparisons of all treatments through RR with 95% CrI can be found in Table 5 . Adverse events were seen predominantly in low frequencies (inferior to 15%), except for hematological events (with a global mean of 27.6%). The lowest frequency was found with cardiac events (4.8%).
As expected, Thal containing regimens presented higher rates of thromboembolic events when compared with other treatment options. Among these thalidomide regimens, TAD and TT2-Thal showed the worst results.
Neurologic AEs were found more commonly in Thal and Bor containing regimens, especially when compared with VAD-based regimens. Also, combined Bor and Thal (VTD) fared worse than a thalidomide only protocol (CTD).
Infectious events were more common in anthracycline containing regimens, like VAD-based and PAD regimens, than in other treatment groups. Of note, high dose dexamethasone monotherapy also showed an unfavorable profile, resulting in significantly more infectious events than PAD, VAD, Z-Dex, and VTD and showing the same behavior trend towards other treatment groups.
Hematological AEs were also found more frequently in anthracycline containing regimens (especially Z-Dex, VAD-based, and PAD regimens), except for TT2-Thal that has also shown a higher rate of events when compared with CTD, DVd, and Dex.
Gastrointestinal AEs occurred significantly more frequently in VTD, CTD, TAD, and TT2-Thal regimens when compared with VAD and Z-Dex.
Cardiac events were significantly more common with TAD regimen over TT2-Thal and DVd, and with TT2-Thal over VAD-based regimen.
| Ranking of treatment regimens
For each outcome evaluated, it was possible to calculate the SUCRA curve values for each treatment option and hierarchically organize them according to the probability of being best among those analyzed (e.g. 0.971 = 97.1% probability of being best). SUCRA values for all outcomes are described in Figure 5 .
Overall, survival and response outcomes were led by Thal, Len, and Bor containing regimens. CRD ranked first in OS outcome, followed by PAD, Dvd, and TD-based regimens (VTD and VTDC data on OS was not available). VTD was the best treatment in PFS outcome, followed by TAD and TT2-Thal, and ranked similarly for OR (followed VTDC and PAD) and CR (followed closely by PAD and TAD).
Safety analysis demonstrated major toxicity profiles occurring in regimens which contained anthracyclines (TAD, PAD, and TT2-Thal), while TD-based and VTDC regimens seemed to be safer regimens.
| DISCUSSION
Many gaps and unanswered questions still linger on MM treatment, many of them inferred on but seldom effectively demonstrated. This This study aimed at transplant-eligible patients; however, one study reported a rate of only 30% of transplantation, 30 possibly due to a shorter follow-up. For the remaining trials, more than half of patients underwent transplantation, attaining an impressive 100% rate in one of them. 44 Bisphosphonate use was reported in the majority of trials.
Risk of bias was systematically present in included trials to a variable extent. Most of it was due to limitations in blinding and/or concealment, or underreporting of methodological details. Although this is undoubtedly a quality shortcoming, most of current RCT in this area follow a similar structure; thus, this group of studies would be considered representative of available evidence.
Survival outcomes in this meta-analysis corroborated current practice of incorporating novel agents (Thal, Len, and/or Bor) into first-line treatments for transplant-eligible patients. An already recognized exception for this is the TD-based regimen, due to its high dose dexamethasone content, which was shown to be an inferior treatment also in the present study. OS data were not available for VTD, and the leading treatment for this endpoint was a Len-based regimen (CRD).
DVd 30 ranked unexpectedly well on OS among these protocols, possibly due to a shorter follow-up time.
Response outcomes reflected findings on survival. VTD ranked first on both OR/CR, corroborating previous recommendations for first-line treatment, even more considering that deeper responses could lead to better post-transplant results. 6 Adverse events had a low frequency overall, and those regimens containing anthracyclines would possibly be responsible for an important amount of them. Anthracyclines were a main part of older regimens but their use on current therapy should be carefully evaluated.
Limitations to this study should be acknowledged. Almost half of selected studies were withdrawn due to the lack of HR reporting.
We also chose not to apply graphical data extraction approaches, 46 due to controversy on its adequacy. Moreover, it is important to emphasize that HR extracted from Cox regression model analyses are prone to bias and incorrectness pending on their non-compliance with model assumptions. 47 Grouping of treatments was complex due to intrinsic minor differences among some of the protocols included in the same arm of comparison, although we have based our similarity assumption on backbone constituents of each regimen. Heterogeneity among protocols included in the same group of comparison should not be overlooked. (together with pipeline drugs), should be able to establish the role of even newer agents on frontline therapy framework and clarify optimal sequence of protocols to be applied on conventional practice.
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